ARTICLE | Clinical News
Basilea starts dermatitis Phase IIIs
October 28, 2004 7:00 AM UTC
Basilea (SWX: BSLN) started Phase III testing of its BAL4079 alitretinoin in severe chronic hand dermatitis refractory to topical treatment. The Phase III program includes two international double-bli...